WO2008031098A1 - Bibliothèques d'acides aminés binaires pour monocorps polypeptidiques de fibronectines de type iii - Google Patents

Bibliothèques d'acides aminés binaires pour monocorps polypeptidiques de fibronectines de type iii Download PDF

Info

Publication number
WO2008031098A1
WO2008031098A1 PCT/US2007/078039 US2007078039W WO2008031098A1 WO 2008031098 A1 WO2008031098 A1 WO 2008031098A1 US 2007078039 W US2007078039 W US 2007078039W WO 2008031098 A1 WO2008031098 A1 WO 2008031098A1
Authority
WO
WIPO (PCT)
Prior art keywords
loop
monobody
library
mbp
loop region
Prior art date
Application number
PCT/US2007/078039
Other languages
English (en)
Inventor
Shohei Koide
Kaori Esaki
Akiko Koide
Original Assignee
The University Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Chicago filed Critical The University Of Chicago
Publication of WO2008031098A1 publication Critical patent/WO2008031098A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Definitions

  • the invention generally relates to libraries of artificial antibodies or monobodies, i.e., single domain antibody mimics.
  • the libraries include a plurality of different monobodies generated by creating diversity in the surface loop regions of natural molecular scaffolds.
  • affinity reagents The ability to engineer proteins, e.g., antibodies, that bind to a given target is a major goal in protein engineering.
  • antibodies are traditionally generated by immunizing animals, recent advances in protein engineering technologies have made it possible to engineer antibody fragments and antibody-like molecules, collectively referred to as "affinity reagents," using recombinant DNA technologies without the use of animals.
  • affinity reagents or antibody mimics
  • affinity reagents are useful in molecular and cellular biology, biotechnology and the pharmaceutical industry.
  • affinity reagents are selected from combinatorial libraries in which a portion (or portions) of a protein/peptide is diversified. Because it is impossible to make a library that completely covers all possible sequences, the design of combinatorial libraries is an extremely important parameter that determines the success and failure of affinity reagent engineering.
  • the antibody framework can be considered as a "molecular scaffold” that present the CDRs, and antibodies with different affinity and/or specificity are generated by changing the amino acid sequences of the CDRs.
  • the amino acid sequence diversity is usually generated at the DNA level.
  • the DNA sequences (codons) for positions at which amino acid diversity is introduced are changed to a combination of nucleotides (degenerate codons) that code for a set of amino acids.
  • the NNN N represents an equal mixture of A, T, G and C
  • the size of recombinant libraries is usually limited by the transformation efficiency (i.e., the efficiency by which DNA can be introduced into a host organism), typically ⁇ 10 10 for E.
  • the library size limit determines the degree of coverage of possible sequence combination for a given library.
  • the six CDRs of standard antibodies typically contain approximately 30 residues. Thus, there are 20 30 possible amino acid sequences, and if one uses the NNK codon (K represents an equal mixture of G and T; 32 possible combinations that encode all 20 amino acids) 32 30 DNA sequences are required to include all possible DNA combinations. Clearly these sizes are far beyond the practical limit for library size.
  • Two complementary approaches have been advanced to reduce the total number of possible sequences in a library.
  • One is to reduce the number of positions that are diversified, and the other is to reduce the number of amino acids used for each position.
  • the former approach i.e., fully randomizing a few positions at a time, has not been very successful in engineering high-affinity binding proteins, probably because protein-protein interaction typically requires a sizable interface (Lo Conte et al., 1999, The atomic structure of protein-protein recognition sites, J. MoI. Biol., 285: 2177-2198).
  • the invention provides methods of engineering binding proteins using molecular scaffolds.
  • the problem of providing a combinational library of affinity reagents of practical size is solved in one aspect, by using the tenth FN3 domain of human fibronectin (FN3fn10) as the molecular scaffold and diversifying up to three loops (BC, DE and FG) of FN3fn10 to construct a combinatorial library.
  • monobodies with novel binding functions can be engineered by screening phage-display libraries of FN3fn10 in which loop regions are diversified by varying loop sequence length or replacement of one or more amino acids with serine or tyrosine or a combination of both.
  • binary amino acids e.g., serine and tyrosine
  • FIG. 1 is a schematic graphic illustrating the concept of a molecular scaffold, showing the variable loops and the target protein that binds them.
  • FIGS. 2 A-B are schematic drawings of the structure of the 10 th type III domain of human fibronectin (FN3fn10), with ⁇ -strands labeled as A-G and the loop regions BC, DE and FG labeled (Koide, et al., 1998, The fibronectin type III domain as a scaffold for novel binding proteins, J. MoI. Biol., 284:1141-1151).
  • FIG. 3A is the amino acid sequence and restriction sites of FN3 ;
  • FIG. 3B is the amino acid sequence and restriction sites of the "shaved" FN3 with introduced serines in boldface, and including the stability-enhancing mutation D7K.
  • FIG. 4 shows tables of S/Y monobodies generated for a variety of target proteins and the associated K d s.
  • FIG. 5 is a graph illustrating the binding of S/Y monobodies for ySUMO and MBP
  • FIG. 6 is a graphic illustrating varying loop length.
  • FIG. 7 shows schematic vector maps of a phage display vector and a yeast surface display vector in accordance with the present invention.
  • FIG. 8 is a representative sensorgram for the interaction of a MBP-binding monobody (MBP-1 , SEQ ID NO:63) with MBP.
  • MBP-1 MBP-binding monobody
  • the monobody was first immobilized to a sensor chip NTA through the HiS 10 tag.
  • MBP 300 nM
  • MBP 300 nM
  • the black curves show the experimental data, and the red curves show the best fit with a K d of 20 nM.
  • FIG. 9 is a table of alignments of the loop sequence regions of different clone monobodies for the three targets, MBP, hSUMO4, and ySUMO, and the respective K d values.
  • FIG. 1OA is the titration curves for three MBP-binding monobodies tested using yeast surface display showing level of MBP binding (PE fluorescence) normalized with respect to the level of monobody display (FITC fluorescence).
  • FIG. 1OB is a SPR sensorgram of the interaction between the MBP-74 monobody and MBP.
  • FIG. 10C- E are bar graphs showing the binding specificity of monobodies tested with three different targets and yeast surface display, where 1OC is hSUMO4, 10D is ySUMO, and 10E iS MBP.
  • FIG. 11A is a schematic of the x-ray crystal structure of the MBP monobody MBP-74 fusion protein.
  • FIG. 11 B and 11C is a schematic of the "binding complex" of MBP and monobody with the MBP fusion partner.
  • FIG. 11 D is the epitope shown on the MBP surface.
  • FIG. 11 E is the epitope of MBP mapped by NMR spectroscopy.
  • FIG. 11 F is a comparison of the backbone conformation of the recognition loops between monobody MBP-74 and wild-type FN3fn10.
  • FIG. 12A-C is a diagram of the stick model of binding interface of the MBP-74 monobody and MBP.
  • FIG. 12D is a bar graph of the buried surface areas of the monobody residues.
  • FIG. 13A is the superposition of ⁇ CD bound to MBP and the monobody paratope residues.
  • FIG. 13B is the comparison of the MBP epitope and ⁇ CD with that of MBP- 74 monobody.
  • FIG. 14 is the HSQC spectra of [ 2 H 1 13 C 1 15 N]-MBP in the absence and presence of the unlabeled MBP-74 monobody by NMR spectroscopy.
  • FIG. 15 is a representation of the interaction between the MBP residues (right side) and the monobody residues (left side).
  • FIG. 16A is a list of the clones occurring by mutation of the MBP-74 monobody sorted by using phage display to bind to MBP.
  • FIG. 16B is a list of the clones occurring by mutation of the MBP-74 monobody sorted by using phage display for binding to V5 epitope tag.
  • FIG. 17A is a model of the paratope of the MBP-74 monobody.
  • FIG. 17B is the paratope of Fab-YSd1.
  • FIG. 17C are bar graphs comparing the amino acid compositions of the binding interfaces for the MBP-74 monobody/MBP complex and the Fab-YSd1.hDR5 complex, the upper panel show the buried surface areas for the paratopes plotted for different amino acid types, and the lower panel for the epitopes.
  • FIG. 18A depicts a schematic drawing of the monobody scaffold with ⁇ -strands labeled, and the FG loop, where amino acid diversity was introduced into the library.
  • FIG. 18B is the schematic alignment of wildtype FN3 FG loop sequence, the single- loop binary library, and two MBP-binding clones selected from the library.
  • FIG. 18C is a SPR sensorgrams for MBP-SL1 , where MBP-SL1 was immobilized on a surface and the association and dissociation of MBP was monitored.
  • FIG. 18D is a table outlining the binding parameters obtained from the SPR analysis for two single-loop monobodies and for MBP-74.
  • the invention provides simplified combinatorial libraries of antibody mimics or monobodies utilizing a molecular (protein) scaffold.
  • the invention provides a combinatorial library for a fibronectin type III (FN3) scaffold.
  • the library includes certain antibody mimics or monobodies in which the loop regions of the scaffold, corresponding to an antigen binding site or pocket, are varied in length and substitution using binary set, i.e., only two amino acids, such as serine and tyrosine.
  • binary set i.e., only two amino acids, such as serine and tyrosine.
  • the number of total possible sequences that are encoded in the library is much smaller and potentially yields a greater percentage of high affinity binders than unrestricted libraries.
  • the combinatorial libraries embodying the principles of the invention are binary libraries of FN3 that produce high affinity monobodies i.e., single domain antibody mimics.
  • the FN3 scaffold has only up to three loops that can be diversified.
  • the maximal number of residues that can potentially form a binding interface is 20-25 residues. Therefore, the interface size of FN3 monobodies are expected to be significantly smaller than that of Fab's. Furthermore, the smaller number of diversified positions in the FN3 monobodies results in a smaller number of possible amino acid sequences that can be coded, which, in turn, results in a smaller chemical diversity of the interface.
  • any and all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof.
  • a range of 20% to 40% can be broken down into ranges of 20% to 32.5% and 32.5% to 40%, 20% to 27.5% and 27.5% to 40%, etc.
  • a peptide or polypeptide is stated as having 7 to 300 amino acids, it is intended that values such as 7 to 25, 8 to 30, 9 to 90 or 50 to 300 are expressly enumerated in this specification.
  • any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc.
  • each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.
  • all language such as “up to,” “at least,” “greater than,” “less than,” “more than” and the like include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above.
  • all ratios disclosed herein also include all subratios falling within the broader ratio. These are only examples of what is specifically intended.
  • “monobody” or “monobodies” is intended to refer to an artificial or synthetic single domain antibody or antibody mimic, i.e., to a binding protein/polypeptide that has a sequence variable domain, and especially to a protein/polypeptide that has one or more variable loop regions.
  • the term refers to a polypeptide which includes a ⁇ -strand domain lacking in disulfide bonds and containing a plurality of ⁇ -strands, two or more loop regions each connecting one ⁇ -strand to another ⁇ -strand, wherein at least one of the two or more loop regions, is characterized by activity in binding a target protein or target molecule.
  • polypeptide monobodies of the invention can include three or more loop regions.
  • the size of such polypeptide monobodies is suitably less than about 30 kDa, more suitably less than about 20 kDa.
  • target refers to any biomolecule of interest for which a binding protein is sought.
  • exemplary targets include, but are not limited to, secreted peptide growth factors, pharmaceutical agents, cell signaling molecules, blood proteins, portions of cell surface receptor molecules, portions of nuclear receptors, steroid molecules, viral proteins, antibodies, portions of antibodies, carbohydrates, enzymes, active sites of enzymes, binding sites of enzymes, portions of enzymes, small molecule drugs, cells, bacterial cells, proteins, molecular affinity's of proteins, surfaces of proteins involved in protein-protein interactions, cell surface epitopes, diagnostic proteins, diagnostic markers, plant proteins, peptides involved in protein-protein interactions, and foods.
  • a library refers to any collection of different proteins/polypeptides.
  • a library may be a collection of polypeptides that have been modified to favor the inclusion of certain amino acid residues, or polypeptides of certain lengths.
  • molecular scaffold or “scaffold” is meant a core molecule or framework, particularly a polypeptide used to select or design a polypeptide frame with specific and favorable properties, such as binding affinity.
  • One or more additional chemical moieties can be covalently attached to, modified in, or eliminated from the core molecule to form a plurality or library of molecules with common structural elements.
  • Characteristics of a scaffold can include having chemical positions where moieties can be attached that do not interfere with binding of the scaffold to a protein binding site, such that the scaffold or library members can be modified to improve binding affinity and/or specificity.
  • the term “modulating” or “modulate” refers to an effect of altering a biological activity, especially a biological activity associated with a particular biomolecule.
  • an agonist or antagonist of a particular biomolecule modulates the activity of that biomolecule, e.g., an enzyme.
  • process steps are carried out at room temperature and atmospheric pressure unless otherwise specified.
  • Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, cell culture, and transgene incorporation (e.g., electroporation, microinjection, lipofection). Enzymatic reactions, oligonucleotide synthesis, and purification steps are performed according to the manufacturer's specifications.
  • the techniques and procedures are performed according to conventional methods in the art and various general references that are provided throughout this document. The procedures herein are generally well known in the art, some of which are provided for the convenience of the reader.
  • the monobodies in accordance with the invention are suitably based on the structure of a fibronectin module of type III (FN3), a common domain found in mammalian blood and structural proteins, as a scaffold. This domain has been estimated to occur in 2% of the proteins sequenced to date, including but not limited to fibronectins, tenscin, intracellular cytoskeletal proteins, and prokaryotic enzymes (Bork and Doolittle, 1992, Proposed acquisition of an animal protein domain by bacteria, Proc. Natl. Acad. Sci.
  • FN3 fibronectin module of type III
  • these scaffolds include, as templates, the tenth module of human FN3 (FN3fn10), which comprises 94 amino acid residues.
  • FN3fn10 does not contain disulfide bonds or metal binding sites, is highly stable and undergoes reversible unfolding (Koide, et al., 1998, The fibronectin type III domain as a scaffold for novel binding proteins, J. MoI.
  • the monobodies exhibit improved biophysical properties, such as stability under reducing conditions and solubility at high concentrations.
  • these monobodies may be readily expressed and folded in prokaryotic systems, such as E. coli, in eukaryotic systems, such as yeast, and in in vitro translation systems, such as the rabbit reticulocyte lysate system.
  • prokaryotic systems such as E. coli
  • eukaryotic systems such as yeast
  • in vitro translation systems such as the rabbit reticulocyte lysate system.
  • these monobodies are extremely amenable to affinity maturation techniques involving multiple cycles of selection, including in vitro selection using RNA-protein fusion technology (Roberts and Szostak, 1997, RNA- peptide fusions for the in vitro selection of peptides and proteins, Proc. Natl. Acad.
  • the molecular scaffold for formation of monobodies in accordance with the invention is the fibronectin type III domain (FN3).
  • FN3 fibronectin type III domain
  • one suitable wild-type FN3 scaffold is the tenth FN3 domain of human fibronectin (FN3fn10), which is illustrated in FIG. 2A-B, and has an amino acid sequence according to FIG. 3A.
  • An even more suitable scaffold is the synthetic "shaved" FN3 scaffold which is the tenth FN3 domain of human fibronectin and in which serines have been introduced for underrepresented amino acids and includes the stability- enhancing mutation D7K as shown in FIG. 3B.
  • Both the "shaved" and wild-type FN3fn10 are characterized by the same structure, namely seven ⁇ -strand domain sequences (designated A through G and six loop regions (AB loop, BC loop, CD loop, DE loop, EF loop, and FG loop) as illustrated in FIG. 2A-B, which connect the seven ⁇ -strand domain sequences.
  • three loops, the BC, the DE, and the FG were varied.
  • the BC loop, DE loop, and FG loop are all located at the same end of the polypeptide monobody, and the BC loop corresponds to residues 21-31 , the DE loop corresponds to residues 51-56, and the FG loop corresponds to residues 75-88.
  • residue 75 of the FG loop has not previously been included and varied in the FG loop.
  • the exposed loop sequences of the FN3fn10 framework tolerate randomization, facilitating the generation of diverse pools of antibody mimics or monobodies.
  • the FN3Fn10 module is not an immunoglobulin, its overall fold is close to that of the variable region of the IgG heavy chain, making it possible to display three fibronectin loops analogous to CDRs in relative orientations similar to those of native antibodies.
  • the antibody mimics or monobodies embodying the principles of the invention possess antigen binding properties that are similar in nature and affinity to those of antibodies, and a loop randomization and shuffling strategy may be employed in vitro that is similar to the process of affinity maturation of antibodies in vivo.
  • the randomization of these three loops does not have an adverse effect on the overall fold or stability of the FN3fn10 framework or scaffolds itself.
  • FN3fn10-based monobodies have been previously reported for several targets, e.g., ubiquitin, estrogen receptor, integrins (Koide, et al., 1998, The fibronectin type III domain as a scaffold for novel binding proteins, J. MoI. Biol., 284:1141-1151 ; Koide et al., 2002, Probing protein conformational changes by using designer binding proteins: application to the estrogen receptor, Proc. Natl. Acad Sci.
  • targets e.g., ubiquitin, estrogen receptor, integrins
  • the monobodies in accordance with the invention are generated by diversifying the amino acid sequences in up to three loops (BC, DE and FG) of FN3fn10 to construct a combinatorial library.
  • At least one loop region sequence includes an amino acid sequence in which a serine or tyrosine or a combination of both (Ser/Tyr or S/Y) is substituted for the loop sequences of the wild-type. Up to all three loops are suitably replaced with S/Y.
  • the loop region sequence can be varied by replacement of one or more amino acids with serine and/or tyrosine from a corresponding loop region in a wild-type or mutant FN3 scaffold. It is also comtemplated that serine/tryptophan may be used in the same manner as described for S/Y to generate libraries of monobodies.
  • the monobodies described herein have no disulfide bonds, which have been reported to retard or prevent proper folding of antibody fragments under certain conditions. Since the scaffolds utilized in the methods of the invention do not rely on disulfides for native fold stability, they are stable under reducing conditions, unlike antibodies and their fragments which unravel upon disulfide bond breakdown.
  • the three loops of FN3fn10 corresponding to the antigen-binding loops of the IgG heavy chain run between amino acid residues 21-31 , 51-56, and 75-88.
  • the length of the first and the third loop, 11 and 12 residues, respectively, fall within the range of the corresponding antigen-recognition loops found in antibody heavy chains, that is,
  • the second loop of FN3fn10 is only 6 residues long, whereas the corresponding loop in antibody heavy chains ranges from 16-19 residues. To optimize antigen binding, therefore, the second loop of FN3fn10 may be extended by 10-13 residues (in addition to being randomized) to obtain the greatest possible flexibility and affinity in antigen binding. Indeed, in general, the lengths as well as the sequences of the CDR-like loops of the monobodies may be randomized during in vitro or in vivo affinity maturation (as described below).
  • the loop regions can also be diversified by varying lengths of the regions, suitably to between 4 and 25 amino acids. As shown in the examples below, all loops appeared to prefer near-wild-type lengths. Specifically, the DE is suitably full length as in the wild-type. The lengths of BC and FG were more amenable to length variations as seen in FIG. 6.
  • the engineering of the monobodies in accordance with the invention can be accomplished at the DNA level via recombinant techniques. Such techniques afford the deletion, insertion, or replacement of amino acids from a corresponding loop region, in a wild-type or other synthetic FN3 scaffold. In other words, recombinant techniques permit diversification of the amino acid residues and the loop length.
  • Deletions can be a deletion of one or more amino acid residues down to substantially four amino acid residues appearing in a particular loop region.
  • Insertions can be an insertion of one or more amino acid residues which is serine or tyrosine up to about 25 amino acid residues, or suitably up to about 15 amino acid residues.
  • Replacements can be replacements of one or more amino acid residues with serine or tyrosine in a particular loop region.
  • the use of serine and tyrosine represents a bias toward amino acids that are prevalent in protein-binding interfaces (See, Mian et al., 1991 , Structure, function and properties of antibody binding sites, J. MoI. Biol., 217:133-151 , incorporated by reference). Further, the construction design eliminates those amino acids that are under- represented and those that may cause undesired complexities.
  • deletions, insertions, and replacements (relative to wild-type) on FN3 scaffolds can be achieved using recombinant techniques beginning with a known nucleotide sequence.
  • a synthetic gene for the tenth domain of FN3 of human fibronectin (FIG. 3A, SEQ ID NO:1) was designed which includes convenient restriction sites for ease of mutagenesis and uses specific codons for high-level protein expression (Gribskov et al., 1984, The codon preference plot: graphic analysis of protein coding sequences and prediction of gene expression, Nucleic Acids Res., 12(1 Pt 2):539-49).
  • FIG. 3A the residue numbering is according to Main et al.
  • the gene was assembled as follows: first the gene sequence was divided into five parts with boundaries at designed restriction sites (FIG. 3); for each part, a pair of oligonucleotides that code opposite strands and have complementary overlaps of about 15 bases was synthesized; the two oligonucleotides were annealed and single strand regions were filled in using the Klenow fragment of DNA polymerase; the double-stranded oligonucleotide was cloned into the pET3a vector (Novagen) using restriction enzyme sites at the termini of the fragment and its sequence was confirmed by an Applied Biosystems DNA sequencer using the dideoxy termination protocol provided by the manufacturer. These steps were repeated for each of the five parts to obtain the whole gene.
  • Kunkel mutagenesis can be utilized to randomly produce a plurality of mutated monobody coding sequences which can be used to prepare a combinatorial library of polypeptide monobodies for screening. Basically, targeted loop regions (or C- terminal or N-terminal tail regions) can be randomized using a degenerate codon.
  • Monobodies in accordance with the invention can be isolated using cell-display-based library technology, wherein the monobodies are selected by exposing a library of polypeptides displayed on the surface of phage, yeast or other host cell, to a target molecule of interest, and isolating those variants that bind to the target.
  • phage display is a well-known method in the art by which variant polypeptides are displayed as fusion proteins to at least a portion of the coat protein on the surface of phage particles.
  • a library of monobodies is created on the surface of filamentous phage viruses by adding monobody genes to the gene that encodes the phage's coat protein. Phage display can be used for high throughput screening of protein interactions.
  • Each phage expresses and displays multiple copies of a single antibody fragment on its surface. Because each phage possesses both the surface-displayed monobody and the DNA that encodes that fragment, the monobody that binds to a target can be identified by amplifying the associated DNA. Similarly, yeast surface display, may be used to isolate high affinity monobodies against a variety of targets. In one embodiment of the invention, the FN3 phage display system may be constructed as described in the examples below.
  • the S/Y library contained ⁇ 10 10 sequences.
  • the sequences were selected through three rounds of phase display and an optional round of yeast surface display.
  • the library so constructed is capable of producing binding proteins, i.e., monobodies, to a variety of targets as seen in the table of FIG. 4. Specific binding of monobodies is also shown in FIG. 5.
  • Nucleic acid molecules encoding the polypeptide monobody can be incorporated into host cells using conventional recombinant DNA technology. Recombinant molecules can be introduced into cells via transformation, particularly transduction, conjugation, mobilization, or electroporation.
  • the DNA sequences are cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al. (1989, 2002). Generally, this involves inserting the DNA molecule into an expression system to which the DNA molecule is heterologous (i.e., not normally present). The heterologous DNA molecule is inserted into the expression system or vector in sense orientation and correct reading frame.
  • the vector contains the necessary elements (promoters, suppressers, operators, transcription termination sequences, etc.) for the transcription and translation of the inserted protein-coding sequences. See, e.g., U.S. Pat. No. 4,237,224 to Cohen and Boyer, which describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase, incorporated herein by reference. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including prokaryotic organisms and eukaryotic cells grown in tissue culture.
  • host-vector systems may be utilized to express the polypeptide monobody or fusion protein which includes a polypeptide monobody.
  • the vector system must be compatible with the host cell used.
  • Host-vector systems include but are not limited to the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; and mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.).
  • the expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used.
  • Suitable host cells include, but are not limited to, bacteria, yeast cells, mammalian cells, etc.
  • Monobodies in accordance with the present invention are well suited for expression as fusion proteins in combinatorial libraries to be screened, i.e., using a yeast or mammalian two-hybrid system.
  • yeast and mammalian two-hybrid systems have been established as standard methods to identify and characterize protein interactions in the nucleus of yeast cells (Fields & Song, 1989, A novel genetic system to detect protein-protein interactions, Journal: Nature, 340:245-246; Uetz & Hughes, 2000, Systematic and large-scale 2-hyrid screens, Current Opinion in Microbiology, 3303-308).
  • yeast-two hybrid system a method to identify and clone genes for proteins that interact with a protein of interest, Proc Natl Acad Sci, 88(21 ):9578-82, incorporated herein by reference) and is commercially available from Clontech (Palo Alto, Calif.).
  • the two-hybrid system or related methodology can be used to screen activation domain libraries for polypeptide monobodies that interact with a known target protein or polypeptide.
  • the inventors successfully selected monobodies using a yeast two-hybrid system as described in the examples below.
  • the present invention relates to a combinatorial library which includes a plurality of fusion polypeptides.
  • Each of the fusion polypeptides within the combinatorial library includes a transcriptional activation domain fused to a fibronectin type III (FN3) polypeptide monobody as described above, with at least one loop region sequence including a combinatorial amino acid sequence which varies by deletion, insertion, or replacement of one or more amino acids with serine or tyrosine or a combination of both from a corresponding loop region in a wild-type FN3 domain of fibronectin.
  • FN3 fibronectin type III
  • the size of the combinatorial library will necessarily vary depending on the size of the combinatorial sequence introduced into the monobody coding sequence (i.e., the number of mutations introduced into a particular loop coding sequence).
  • the combinatorial library is preferably at least about 10 3 in size, affording at least about 10 5 transformed cells. Therefore, while some redundancy may exist for each individual combinatorial amino acid sequence, considering the total number of transformants, the combinatorial sequence in each individual transformant differs from substantially all other combinatorial sequences present in the combinatorial array of transformants.
  • each polypeptide monobody can be the result of deletions, insertions, or replacements of the type described above.
  • the combinatorial amino acid sequence is at least about 4 amino acids in length, including one or more deletions, insertions, or replacements. In other aspects of the present invention, the combinatorial amino acid sequence is at least about 25 amino acids in length, including one or more deletions, insertions, or replacements.
  • any target protein that does not self-activate the reporter gene can be used.
  • the two hybrid system is not suitable for membrane-bound targets.
  • the split ubiquitin Johnsson & Varshavsky, 1994, Split ubiquitin as a sensor of protein interactions in vivo, Proc Natl Acad Sci USA, 91 (22): 10340-4) or dihydroforate reductase reconstitution can be used (Pelletier et al., 1998, Oligomerization domain-directed reassembly of active dihydrofolate reductase from rationally designed fragments, Proc Natl Acad Sci USA, 95(21):12141-6).
  • the target protein can be any protein or polypeptide.
  • targets used in invention included APC22356, APC35945, MBP (maltose binding protein), APC25517, yeast SUMO (ySUMO) and human SUMO4 (hSUMO4).
  • the monobodies in accordance with the invention may be developed to bind any target of interest.
  • Monobodies or nucleic acids encoding them may be of therapeutic value, i.e., used for therapeutic administration to modulate or modify the activity of the target protein in vivo.
  • Monobodies may be employed in place of antibodies in all areas in which antibodies are used including, research, therapeutic and diagnostic fields.
  • it is suitable for polypeptide monobodies be prepared in substantially pure form. This can be performed according to standard procedures. Typically, this involves recombinant expression of the desired polypeptide monobody by a host cell, propagation of the host cells, lysing the host cells, and recovery of supernatant by centrifugation to remove host cell debris. The supernatant can be subjected to sequential ammonium sulfate precipitation.
  • the fraction containing the polypeptide monobody of the invention is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the polypeptide monobodies. If necessary, the protein fraction may be further purified by HPLC.
  • the isolation and purification of polypeptide monobodies in particular, has previously been reported by Koide et al. (Koide et al.,1998, The fibronectin type III domain as a scaffold for novel binding proteins, J. MoI. Biol. 284:1141-1151).
  • polypeptide monobodies themselves or nucleic acids encoding them are administered alone or in combination with pharmaceutically or physiologically acceptable carriers, excipients, or stabilizers, or in solid or liquid form such as, tablets, capsules, powders, solutions, suspensions, or emulsions, they may, suitably formulated, be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneal ⁇ , by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.
  • the polypeptide monobodies or nucleic acids can be administered intravenously.
  • compositions of the monobodies or nucleic acids in accordance with the present invention may be formulated in accordance with routine procedures as compositions adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition also may include a solubilizing agent and a local anesthetic such as lidocaine to ease pain at the site of the injection.
  • ingredients are supplied either separately or mixed together in unit dosage form; for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • Solutions or suspensions of ingredients can be prepared in a physiologically acceptable diluent with a pharmaceutical carrier.
  • a pharmaceutical carrier include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers.
  • Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
  • water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
  • composition is to be administered by infusion, it can be dispensed by an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • the polypeptide monobodies or nucleic acids in solution or suspension may be packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • suitable propellants for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants.
  • the materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
  • a number of known delivery techniques can also be utilized for the delivery into cells, of either the polypeptide monobodies themselves or nucleic acid molecules which encode them. Regardless of the particular method of the invention which is practiced, when it is desirable to contact a cell (i.e., to be treated) with a polypeptide monobody or its encoding nucleic acid, it is preferred the contacting be carried out by delivery of the polypeptide monobody or its encoding nucleic acid into the cell.
  • liposomes One approach for delivering polypeptide monobody or its encoding DNA into cells involves the use of liposomes. Basically, this involves providing the polypeptide monobody or its encoding DNA to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the polypeptide monobody or DNA into the cell.
  • Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature.
  • Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.
  • active drug release involves using an agent to induce a permeability change in the liposome vesicle.
  • Liposome membranes can be constructed so that they become destabilized when the environment becomes acidic near the liposome membrane (Wang & Huang, 1987, phi-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse, Proc Natl Acad Sci USA, 84(22):7851-5, incorporated by reference).
  • liposomes When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.
  • the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to modulate or alter drug release to achieve "on demand” drug delivery. The same problem exists for pH- sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release.
  • This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.
  • polypeptide monobodies An alternative approach for delivery of polypeptide monobodies involves the conjugation of the desired polypeptide monobody to a polymer that is stabilized to avoid enzymatic degradation of the conjugated monobody.
  • Conjugated proteins or polypeptides of this type are described in U.S. Pat. No. 5,681 ,811 to Ekwuribe, incorporated by reference.
  • the protein can include a ligand domain and, e.g., a polypeptide monobody which has activity to bind a cellular target (e.g., a nuclear receptor or other cellular protein).
  • the ligand domain is specific for receptors located on a target cell.
  • DNA molecules encoding the polypeptide monobody can be delivered into the cell. Basically, this includes providing a nucleic acid molecule encoding the polypeptide monobody and then introducing the nucleic acid molecule into the cell under conditions effective to express the polypeptide monobody in the cell. Preferably, this is achieved by inserting the nucleic acid molecule into an expression vector before it is introduced into the cell.
  • an adenovirus vector When transforming mammalian cells for heterologous expression of a polypeptide monobody, an adenovirus vector can be employed.
  • Adenovirus gene delivery vehicles can be readily prepared and utilized given the disclosure provided in Berkner (Berkner, 1988, Development of adenovirus vectors for the expression of heterologous genes, Biotechniques, 6(7):616-29) and Rosenfeld et al. (Rosenfeld et al., 1991 , Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo, Science, 252(5004): 374), incorporated by reference.
  • Adeno-associated viral gene delivery vehicles can be constructed and used to deliver a gene to cells.
  • adeno-associated viral gene delivery vehicles in vivo is described in Flotte et al. (Flotte et al., 1993, Prospects for virus-based gene therapy for cystic fibrosis, J Bioenerg Biomembr., 25(1):37-42) and Kaplitt et al. (Kaplitt et al., 1994, Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain, Nature Genetics, 8(2): 148-54). Additional types of adenovirus vectors are described in U.S. Pat. No.
  • Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired polypeptide monobody into a target cell.
  • One such type of retroviral vector is disclosed in U.S. Pat. No. 5,849,586 to Kriegler et al, incorporated by reference.
  • infective transformation system Regardless of the type of infective transformation system employed, it should be targeted for delivery of the nucleic acid to a specific cell type.
  • a high titer of the infective transformation system can be injected directly within the tumor site so as to enhance the likelihood of tumor cell infection.
  • the infected cells will then express the desired polypeptide monobody, allowing the polypeptide monobody to modify the activity of its target protein.
  • Dosages to be administered can be determined according to known procedures, including those which balance both drug efficacy and degree of side effects.
  • the amount of monobody agent to be administered depends on the precise formulation selected; the disease or condition of the patient and its severity; the route of administration; the health and weight of the patient; the existence of other concurrent treatment, if any; the frequency of treatment, the nature of the effect desired, for example, inhibition of tumor metastasis; and the judgment of the skilled practitioner.
  • a dose of a monobody agent for treating a patient is an amount sufficient to modulate or modify the activity of the target protein.
  • the number of variables in regard to an individual treatment regimen is large, and a considerable range of doses is expected.
  • "Shaved" FN3fn10 was constructed by replacing under-represented amino acids with Ser, i.e., introducing the D3S, P25S, A26S, V27S, T28S, R30S, V75S, T76S, R78S, G77S, G79S, D80S, P82S, and A83S mutations in the FN3fn10 gene by Kunkel mutagenesis.
  • DNA fragment that encodes signal sequence of DsbA was fused to the gene for "shaved" FN3fn10 using PCR, and the fusion gene was cloned into the phage display vector pAS38 (Koide, et al., 1998, The fibronectin type III domain as a scaffold for novel binding proteins, J. MoI. Biol., 284:1141-1151), resulting in pDsbFNshavedp3.
  • the vector map is shown in FIG. 7.
  • the initial S/Y library was constructed by introducing diversity at all positions in the three loops (BC, DE, and FG) as follows.
  • BC-loop residues 21-31
  • residues 25-28 were replaced with 4 to 10 residues of the S/Y combination
  • residue 30 was replaced with a single S/Y combination.
  • Val27 was unchanged because of its importance for the FN3fn10 stability.
  • residues 52-55 were replaced with 4 to 10 residues of the S/Y combination.
  • residues 75-88 residues 75-85 were replaced with 7 to 15 residues of the S/Y combination, and K86 was replaced with Ser.
  • the second-generation library was constructed as follows.
  • the BC loop contained 4- 8 residues of the S/Y combination for residues 25-28 and a single S/Y combination for R30.
  • G52-S55 In the DE-loop (G52-S55), G52 was replaced with the S/Y/G combination and residues 53-55 were replaced with 3 residues of the S/Y combination.
  • the FG loop was diversified in the same manner as the first-generation library as described above.
  • Target proteins were conjugated with a cleavable biotinylation reagent as follows. A target protein was dissolved in 5OmM MOPS/NaOH buffer, pH 7.0 containing 10OmM
  • the second and third rounds of selection were performed using a King Fisher magnetic beads handler (Thermo).
  • approximately 10 11 of amplified phagemid particles from the first round were mixed with IOpmol of biotinylated target in 100 ⁇ l TBS-BSA (i.e., the target concentration was 10OnM).
  • the target concentration was 10OnM.
  • 20 ⁇ g of SAV-beads were added to capture the biotinylated target-phage complexes and incubated for 15 min.
  • the target molecules After washing the beads 4 times with TBS-BSA, the target molecules (with bound phagemids) were released from the beads by cleaving the disulfide linker between the protein and biotin with elution buffer (2OmM Tris (pH8), 10OmM DTT). Recovered phagemids were used to infect 1.2mL of log-phase XL-1 Blue cells, and phagemids were amplified in the presence of 0.2mM IPTG in 2xYT + ampicillin. The third round was performed in the same manner as the second round except that the target concentration was reduced to 20-50 nM.
  • Example 5 Yeast surface display vector construction
  • a yeast surface display vector for monobodies was constructed from pYD1 (Invitrogen) using yeast homologous recombination.
  • the gene for a Monobody of interest was inserted between Nhel and Xhol sites of pYD1 using yeast homologous recombination (Ma et al., 1987, Plasmid construction by homologous recombination in yeast, Gene 58, 201-16; Raymond et al., 1999, General method for plasmid construction using homologous recombination, Biotechniques 26:134-8,140-1 , incorporated by reference).
  • Yeast cells were transformed using the method of Gietz (Gietz & Woods, 2001 , Genetic transformation of yeast, Biotechniques 30:816-828, incorporated by reference).
  • the resulting plasmid, pGalAgaMB expresses Aga2- monobody-V5 tag-His tag fusion protein under the control of a galactose-inducible promoter.
  • the plasmid map is shown in FIG. 7.
  • Example 6 Yeast surface display and screening
  • Monoclonal anti-V5 IgG and anti-mouse IgG-fluorescein isothiocyanate (FITC) conjugate were purchased from Sigma.
  • Neutravidin-PE (NAV-PE) conjugate was purchased from Molecular Probes.
  • Yeast surface display was performed generally according to Boder and Wittrup (Boder & Wittrup, 2000, Yeast surface display for directed evolution of protein expression, affinity, and stability, Methods Enzymol 328, 430-44, incorporated by reference).
  • the mixture of genes for the enriched monobodies were amplified using primers that contain identical sequences to the 5 1 and 3' flanking regions of the monobody gene in the yeast display vector pGalAgaMB.
  • Saccharomyces cerevisiae EBY100 was transformed with the PCR fragments and linearized pGalAgaMB to make a sub- library.
  • Yeast cells were grown in the presence of 2% galactose at 3O 0 C for 24 hours in order to induce the Aga2-monobody fusion proteins on the yeast cell surface. Then they were incubated with either 5OnM of a biotinylated target for 40min.
  • Example 7 Yeast surface display analysis of individual clones and K d measurements
  • amino acid sequences of isolated monobodies were deduced by PCR-amplifying their genes and determining their DNA sequences.
  • Table 1 lists the amino acid sequences (with corresponding SEQ ID NOs) obtained for the three loop regions, BC (amino acids 21-31), DE (amino acids 51-56) and FG
  • Table 1 Listing of sequences of monobody clones loop regions.
  • An E. coli expression vector, pHFT2 was constructed by replacing the HiS 6 segment of the expression vector pHFT1 (Huang et al.,2006, Conformation-specific affinity purification of proteins using engineered binding proteins: Application to the estrogen receptor, Protein Expr Purif 47, 348-354, incorporated by reference) with a HiS 10 sequence.
  • a monobody gene obtained from library sorting was cloned between the BamHI-Xhol sites by standard PCR cloning methods.
  • BL21(DE3) cells Novagen
  • BL21(DE3) cells Novagen
  • the enriched pools of monobody clones were transferred into the yeast- display format and performed one round of sorting.
  • the Y/S monobodies exhibited clear and distinct consensus sequence for each target, with monobodies to different targets showing distinct loop length distribution (FIG. 9).
  • the obtained cloned monobodies used all the designed lengths of the BC and FG loops except 12 residue-long for FG, suggesting that the BC and FG loops do not have a preferred length.
  • the DE loop in contrast, all of the selected clones were four residues long, suggesting a strong preference imposed by the scaffold.
  • Amino acid sequences of individual clones identified at least two classes of monobodies for each target (FIG. 9, and Table 1).
  • the amino acid sequences of both BC and FG loops are distinctly different classes of monobodies (e.g. MBP-74 versus MBP-32), suggesting that these loops have mutual influence on each other's sequence and cooperatively form a binding interface.
  • the K d values of representative clones ranged from 5 nM to 90 nM (FIG. 9 and 10A).
  • the monobodies showed low levels of cross-reactivity to non-cogate targets, but some clones that cross-react with multiple targets (e.g. hSUMO4-39 and MBP-73, FIG. 10C-E).
  • the selected monobodies can discriminate hSUMO4 and ySOMO that have 40% sequence identity (FIG. 10 C-D), showing that Y/S monobodies achieve a good level of binding specificity.
  • the MBP-monobody fusion protein was crystallized in 20% polyethyleneglycol-1000, 0.1 M Na/K phosphate buffer and 0.2 M NaCI, pH 6.5 using the sitting drop vapor diffusion method. Crystals were frozen in an 80% mixture of this solution combined with 20% glycerol as cryoprotectant.
  • the X-ray diffraction data was collected at APS beamline 24-ID (Advanced Photon Source at Argonne National Laboratory). Crystal data and data collection statistics is summarized in Table 2.
  • X-ray diffraction data was processed and scaled with HKL2000. The structures were determined by molecular replacement using multi-copy search with two different models with the program MOLREP in CCP4.
  • the MBP structure (PDBI: 1 DBM) was used as a search model, along with the FN3 structure (PDBID:1 FNA).
  • the rigid body refinement was carried out with CNS1.1.
  • the SigmaA-weighted 2Fobs-Fcalc and Fobs-Fcalc Fourier maps were calculated and examined.
  • the model building was carried out using the Turbo-Frodo program 10.
  • the simulated annealing and the search for water molecules were performed in CNS1.1.
  • the TLS (Translation/Libration/Screw) and bulk solvent parameters, restrained temperature factor, and final positional refinement were completed with REFMAC5.
  • Molecular graphics were generated using PyMOL.
  • V H H structures that bind to a cleft (PDB IDs: 1 KXQ, 1 KXT, 1 SQ2, 1 JTT, 1 RJC, 1 RI8, 1 ZVY, and 1 ZV5).
  • the monobody scaffold (excluding the three recognition loops) and the corresponding part of the wild-type FN3 (PDB code, 1 FNF) had a Ca rmsd value of 0.54 A, indicating that the FN3fn10 scaffold is essentially unaffected by the extensive mutations in the loops.
  • the recognition loops of the monobody segment interact with the sugar-binding cleft of the MBP segment of an adjacent fusion protein (Fig. 11C).
  • this combination of monobody and MBP is referred to as the "binding complex” and the interface between them as the “binding interface.”
  • the interaction interface of MBP is referred to as the epitope and that of the monobody as the paratope.
  • the binding interface buries 749 A2 of monobody surface is comprised of 16 residues of the monobody and 22 residues of MBP (interface residues are defined as those with buried surface area > 5 A2; FIG. 15).
  • the DE loop contains the wild-type sequence, all three recognition loops are involved in the interaction. Both the epitope and the paratope are bisected by a deep unfilled cavity, resulting in two distinct sets of contacts (FIG. 11 D and FIG. 12A).
  • the monobody FG loop and a part of the scaffold interact with the "bottom" lobe of MBP, and the BC and DE loops together with a single Tyr residue from the FG Loop interact with the "top" lobe (FIG. 12A).
  • the contacts made by the monobody scaffold residues are potentially due to lattice packing, because the contact residues are mostly polar and charged and NMR epitope mapping data show little to no chemical shift perturbation in this area (FIG. 11 E).
  • the FG-loop residues contribute the bulk of the interface surface (513 A2; FIG. 12D) and mediate contact with MBP almost exclusively through the side chain atoms.
  • Tyr residues in this loop (FIG. 2B) 1 three interact closely with aromatic residues of MBP (FIG. 12B). They form a central hydrophobic patch that is surrounded by a more polar periphery consisting of the hydroxyl groups of five Tyr residues (FIG. 12B).
  • the remaining Tyr residues do not contribute to this contact: Y82 lies against the backside of the Tyr cluster that form the binding interface, and Y77 stretches away.
  • the BC and DE loops together with Y77 interact with three charged residues on the "top" lobe of MBP (FIG. 12A and C).
  • This interface nearly completely buries K42, E44 and E45 of MBP to account for 149 A2 of the monobody interface surface area.
  • the majority of the contacts here are mediated by the backbone atoms.
  • the carbonyl groups of S27 and V29 of the BC loop and the hydroxyl group of Y77 form hydrogen bonds with the buried K42 of MBP.
  • nearby E44 and E45 of MBP form hydrogen bonds with the hydroxyl groups of Tyr77 and Ser53, respectively.
  • These GIu residues may compensate for the burial of K42's ⁇ -amino group.
  • each monobody molecule forms a large binding interface (520 A) with the MBP molecule to which it is fused as well as a 214 A2 contact with a symmetry-related MBP. Together with the binding interface, 28% of the total monobody surface is buried in the crystal structure.
  • FIG. 13B A structural comparison of the MBP/monobody complex with MBP complexed with its ⁇ CD substrate revealed that the MBP epitopes for ⁇ CD and the monobody share 12 residues that have nearly identical conformations in the two structures (FIG. 13B).
  • Many ⁇ CD structural elements are closely mimicked by the monobody binding loop structures (FIG. 13A).
  • the aromatic ring of the FG loop Tyr shows striking overlap with the sugar rings of ⁇ CD, and they utilize the same hydrophobic contacts.
  • many of the hydroxyl groups of ⁇ CD are emulated by the Tyr hydroxyls and backbone carbonyls, which resulted in conservation of a similar hydrogen bonding pattern.
  • Example 12 NMR of MBP and a monobody
  • Amide cross peaks were classified into four categories: strongly affected, a peak that migrates more than two linewidths; weakly affected, a peak exhibiting a significantly reduced intensity at the same position as in the free spectrum, or a peak that has a corresponding peak in the complex spectrum to the vicinity (within two linewidths) of its original position in the free spectrum; not affected; and excluded from analysis, a peak that overlaps with another in the spectra.
  • Example 13 Production of monobodies from a single-loop binary library
  • the library was sorted using maltose-binding protein (MBP) as a target.
  • MBP maltose-binding protein
  • the progress of sorting was monitored by determining the number of recovered phages (Table 4).
  • the "enrichment ratio" is the ratio of the number of phages recovered from sorting performed with the target to that from sorting without the target, and a high ratio indicates a substantial enrichment of the phages specifically binding to the target. In our experience, usually more than 50% of clones are target-specific binders when the enrichment ratio is 10 or greater.
  • the enrichment factor was 60 in the fourth round, and 90% of the sorted clones were MBP-binders as judged by phage ELISA method.
  • FIG. 18B shows the amino acid sequences of the selected clones. There were only two unique sequences among the selected 15 clones. MBP-SL1 that appeared 14 times had a pattern of tyrosine-serine followed by multi tyrosine (FIG. 18B), and the loop-length was two residues shorter than the wild type. The other clone, MBP-SL2, that appeared only once, also had a similar pattern but Y81 was replaced with a Ser, and the loop-length was one residue shorter than SL1. Kd values of the single-loop monobodies, as measured by surface plasmon resonance (SPR), were 213nM and 184nM, respectively (FIG. 18C and 18D).
  • SPR surface plasmon resonance
  • the monobodies were also specific, as they showed no binding to ribonuclease A, cytochrome C, or yeast SUMO, even at a target concentration of 5 ⁇ M in SPR experiments. Table 4. Phage numbers and enrichment ratios for monobody library sorting
  • NP not performed.
  • ND Not determined.
  • the enrichment ratio is determined as the number of recovered phages from target(+) selection over that from target(-) selection.
  • the FG loop sequence of MBP-SL1 is identical to that of an MBP-binding monobody that was previously obtained from a library in which three loops were randomized described above.
  • the MBP-binding monobody, MBP-74 had two mutated loops, and its FG loop was the same as that of MBP-SL1 (FIG. 18B), but their BC loop sequences were distinct.
  • the affinity of the monobodies MBP-SL1 (SEQ ID NO:65) and MBP-SL2 (SEQ ID NO:66) was only slightly reduced relative to that of monobody MBP-74 whose Kd is 135nM (FIG. 18D), suggesting the dominant role of the FG loop in binding to MBP.
  • a 20 amino acid randomization to make a display library has long been standard protocol. Including all 20 amino acid types greatly increases chemical diversity over the binominal diversity; however, it also makes the number of encoded sequences very large. For example, for randomizing 9 residues (same loop length as clone MBP-SL1), theoretical library size is 3.5 x 10 13 , which far exceeds the practical library size achievable with the current phage display techniques ( ⁇ 10 11 ). Consequently, only a small fraction of encoded sequences can be experimentally sampled.
  • the Y/S binary encoded in a single loop produced binding proteins, thus defining the ultimate baseline for the effectiveness of the Y/S binary diversity.
  • the "hard randomized" library failed in the same context.
  • the AII-9- library (contained 10 10 independent clones) contained only about 0.1% of all sequences encoded by the design (3.5 x 10 13 ). This sparse sampling of the encoded sequences resulted in a failure to recover MBP-binding sequences that are clearly present among them, for example, the sequence of MBP-SL1.
  • Second, some of the additional amino acids available in the AII-9 library could disrupt a binding surface.
  • a large fraction of AII-9 encoded sequences contains one or more "counter-binding" amino acid. It is important to note that these two problems are related. If one can sample the sequences of the AII-9-library, one would be able to select a binding clone even in the presence of a larger number of nonbinding clones. Because the size of experimental combinatorial libraries is limited, encoding ail amino acid types in a library is indeed counterproductive. The effectiveness of the Y/S binary library arises from its high content of binding sequences, the absence of the counter-binding amino acids, and the small library size that allows nearly complete sampling.
  • the present invention provides methods of engineering binding proteins using molecular scaffolds.
  • the invention uses the tenth FN3 domain of human fibronectin (FN3fn10) as the molecular scaffold, diversifies up to three loops (BC, DE and FG) of FN3fn10 to construct a combinatorial library.
  • the library includes certain antibody mimics or monobodies in which the loop regions of the scaffold, corresponding to an antigen binding site or pocket, are varied using only two amino acids, serine and tyrosine.
  • the combinatorial libraries in accordance with the present invention are binary libraries of FN3 that produce high affinity monobodies.
  • the library includes certain antibody mimics or monobodies in which the loop regions of the scaffold, corresponding to an antigen binding site or pocket, are varied using only two amino acids, serine and tyrosine.
  • the combinatorial libraries in accordance with the present invention are binary libraries of FN3 that produce high affinity monobodies.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne en général des bibliothèques de monocorps polypeptidiques de fibronectine de type III, qui comprennent plusieurs monocorps différents générés par création d'une diversité dans les régions de boucle de surface d'échafaudages moléculaires naturels au moyen de deux acides aminés seulement.
PCT/US2007/078039 2006-09-09 2007-09-10 Bibliothèques d'acides aminés binaires pour monocorps polypeptidiques de fibronectines de type iii WO2008031098A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84335706P 2006-09-09 2006-09-09
US60/843,357 2006-09-09

Publications (1)

Publication Number Publication Date
WO2008031098A1 true WO2008031098A1 (fr) 2008-03-13

Family

ID=38941897

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078039 WO2008031098A1 (fr) 2006-09-09 2007-09-10 Bibliothèques d'acides aminés binaires pour monocorps polypeptidiques de fibronectines de type iii

Country Status (1)

Country Link
WO (1) WO2008031098A1 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023184A3 (fr) * 2007-08-10 2009-07-09 Protelix Inc Bibliothèques universelles de domaines de liaison de la fibronectine de type iii
WO2010060095A1 (fr) 2008-11-24 2010-05-27 Bristol-Myers Squibb Company Molécules liantes bispécifiques egfr/igfir
WO2009142773A3 (fr) * 2008-05-22 2010-08-05 Bristol-Myers Squibb Company Protéines à domaines d’échafaudage à base de fibronectine multivalente
WO2011140086A2 (fr) 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Molécules de liaison à l'albumine sérique
WO2011150133A2 (fr) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
WO2012142515A2 (fr) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Protéines hybrides fc comprenant de nouveaux lieurs ou agencements
WO2012158678A1 (fr) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Procédés de maintien de la pegylation de polypeptides
WO2012158739A1 (fr) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Procédés améliorés pour la sélection de protéines de liaison
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
US9212231B2 (en) 2010-04-13 2015-12-15 Medimmune, Llc TRAIL R2-specific multimeric scaffolds
US20150361159A1 (en) * 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US9234028B2 (en) 2008-02-14 2016-01-12 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US9328157B2 (en) 2003-12-05 2016-05-03 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US9416170B2 (en) 2011-10-31 2016-08-16 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US20180208678A1 (en) * 2015-07-17 2018-07-26 The University Of Chicago Methods and composition for modifying enzymes
US10041064B2 (en) 2008-12-16 2018-08-07 Novartis Ag Yeast display systems
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
US10787498B2 (en) 2013-02-06 2020-09-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
US11555062B2 (en) 2011-10-11 2023-01-17 Viela Bio, Inc. Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
US11680091B2 (en) 2018-02-23 2023-06-20 The University Of Chicago Methods and composition involving thermophilic fibronectin type III (FN3) monobodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004523A2 (fr) * 2000-07-11 2002-01-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
WO2002032925A2 (fr) * 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004523A2 (fr) * 2000-07-11 2002-01-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
WO2002032925A2 (fr) * 2000-10-16 2002-04-25 Phylos, Inc. Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FELLOUSE F A ET AL: "Molecular Recognition by a Binary Code", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 348, no. 5, 20 May 2005 (2005-05-20), pages 1153 - 1162, XP004870065, ISSN: 0022-2836 *
KOIDE A ET AL: "The fibronectin type III domain as a scaffold for novel binding proteins", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 284, no. 4, 11 December 1998 (1998-12-11), pages 1141 - 1151, XP004455886, ISSN: 0022-2836 *
KOIDE AKIKO ET AL: "High-affinity single-domain binding proteins with a binary-code interface", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 16, April 2007 (2007-04-01), pages 6632 - 6637, XP002466093, ISSN: 0027-8424 *
XU LIHUI ET AL: "Directed evolution of high-affinity antibody mimics using mRNA display", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 9, no. 8, August 2002 (2002-08-01), pages 933 - 942, XP002293439, ISSN: 1074-5521 *

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862758B2 (en) 2003-12-05 2018-01-09 Bristol-Myers Quibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US9328157B2 (en) 2003-12-05 2016-05-03 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US10995131B2 (en) 2003-12-05 2021-05-04 Bristol-Myers Squibb Company Libraries of modified fibronectin type III tenth domain-containing polypeptides
US11149077B2 (en) 2006-11-22 2021-10-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US10221232B2 (en) 2006-11-22 2019-03-05 Bristol-Myers Squibb Company Methods of treating cancer by administering IGF-IR binding molecules
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US8680019B2 (en) 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US9376483B2 (en) 2007-08-10 2016-06-28 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A3 (fr) * 2007-08-10 2009-07-09 Protelix Inc Bibliothèques universelles de domaines de liaison de la fibronectine de type iii
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8697608B2 (en) 2007-08-10 2014-04-15 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US9176129B2 (en) 2007-10-31 2015-11-03 Medimmune, Llc Protein scaffolds
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
US9234028B2 (en) 2008-02-14 2016-01-12 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US9920108B2 (en) 2008-02-14 2018-03-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US10781247B2 (en) 2008-02-14 2020-09-22 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
CN102099373A (zh) * 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
EP2799448A1 (fr) * 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Protéines de domaine d'échafaudage à base de fribronectine multivalente
US9902762B2 (en) 2008-05-22 2018-02-27 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US10774130B2 (en) 2008-05-22 2020-09-15 Bristol-Myers Squibb Company Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
US8221765B2 (en) 2008-05-22 2012-07-17 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
WO2009142773A3 (fr) * 2008-05-22 2010-08-05 Bristol-Myers Squibb Company Protéines à domaines d’échafaudage à base de fibronectine multivalente
US8728483B2 (en) 2008-05-22 2014-05-20 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US10183987B2 (en) 2008-11-24 2019-01-22 Bristol-Myers Squibb Company Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules
US9771411B2 (en) 2008-11-24 2017-09-26 Bristol-Myers Squibb Company Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules
EP3029064A1 (fr) 2008-11-24 2016-06-08 Bristol-Myers Squibb Company Molécules de liaison bispécifiques egfr/igfir
US9017655B2 (en) 2008-11-24 2015-04-28 Bristol-Myers Squibb Company Bispecific EGFR/IGFIR binding molecules
US10954286B2 (en) 2008-11-24 2021-03-23 Bristol-Myers Squibb Company Bispecific EGFR/IGFIR binding molecules
WO2010060095A1 (fr) 2008-11-24 2010-05-27 Bristol-Myers Squibb Company Molécules liantes bispécifiques egfr/igfir
US10301616B2 (en) 2008-12-16 2019-05-28 Novartis Ag Yeast display systems
US10041064B2 (en) 2008-12-16 2018-08-07 Novartis Ag Yeast display systems
US9139825B2 (en) 2009-10-30 2015-09-22 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
US10253313B2 (en) 2009-10-30 2019-04-09 Novartis Ag Universal fibronectin type III bottom-side binding domain libraries
US9212231B2 (en) 2010-04-13 2015-12-15 Medimmune, Llc TRAIL R2-specific multimeric scaffolds
US8969289B2 (en) 2010-05-03 2015-03-03 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2011140086A2 (fr) 2010-05-03 2011-11-10 Bristol-Myers Squibb Company Molécules de liaison à l'albumine sérique
US9540424B2 (en) 2010-05-03 2017-01-10 Bristol-Myers Squibb Company Serum albumin binding molecules
US10221438B2 (en) 2010-05-03 2019-03-05 Bristol-Myers Squibb Company Serum albumin binding molecules
US10934572B2 (en) 2010-05-03 2021-03-02 Bristol-Myers Squibb Company Serum albumin binding molecules
WO2011150133A2 (fr) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
US11161893B2 (en) 2010-05-26 2021-11-02 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP3091028A1 (fr) 2010-05-26 2016-11-09 Bristol-Myers Squibb Company Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
US10273286B2 (en) 2010-05-26 2019-04-30 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
EP3896083A1 (fr) 2011-04-13 2021-10-20 Bristol-Myers Squibb Company Protéines de fusion fc comprenant de nouveaux lieurs et arrangements
US9469676B2 (en) 2011-04-13 2016-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US10214579B2 (en) 2011-04-13 2019-02-26 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012142515A2 (fr) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Protéines hybrides fc comprenant de nouveaux lieurs ou agencements
EP3144320A1 (fr) 2011-04-13 2017-03-22 Bristol-Myers Squibb Company Protéines de fusion fc comprenant de nouveaux lieurs et arrangements
EP3415528A2 (fr) 2011-04-13 2018-12-19 Bristol-Myers Squibb Company Protéines de fusion fc comprenant de nouveaux lieurs et arrangements
US10150962B2 (en) 2011-05-17 2018-12-11 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US11060085B2 (en) 2011-05-17 2021-07-13 Bristol-Myers Squibb Company Methods for the selection of binding proteins
WO2012158678A1 (fr) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Procédés de maintien de la pegylation de polypeptides
US11913137B2 (en) 2011-05-17 2024-02-27 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US10898538B2 (en) 2011-05-17 2021-01-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
WO2012158739A1 (fr) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Procédés améliorés pour la sélection de protéines de liaison
EP3318880A1 (fr) 2011-05-17 2018-05-09 Bristol-Myers Squibb Company Procédés améliorés pour la sélection de protéines de liaison
US9347058B2 (en) 2011-05-17 2016-05-24 Bristol-Myers Squibb Company Methods for the selection of binding proteins
US11555062B2 (en) 2011-10-11 2023-01-17 Viela Bio, Inc. Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
US9765132B2 (en) 2011-10-31 2017-09-19 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9416170B2 (en) 2011-10-31 2016-08-16 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US10464995B2 (en) 2011-10-31 2019-11-05 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US10604556B2 (en) 2011-10-31 2020-03-31 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US11279751B2 (en) 2011-10-31 2022-03-22 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US11408093B2 (en) 2011-10-31 2022-08-09 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
US10406212B2 (en) 2012-09-13 2019-09-10 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US9662373B2 (en) 2012-09-13 2017-05-30 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8993265B2 (en) 2012-09-13 2015-03-31 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US11813315B2 (en) 2012-09-13 2023-11-14 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US10245302B2 (en) 2012-09-13 2019-04-02 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8933199B2 (en) 2012-09-13 2015-01-13 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US9493546B2 (en) 2012-09-13 2016-11-15 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US8853154B2 (en) 2012-09-13 2014-10-07 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind to myostatin
US11447538B2 (en) 2013-02-01 2022-09-20 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20150361159A1 (en) * 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US10787498B2 (en) 2013-02-06 2020-09-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
US11512124B2 (en) 2013-02-06 2022-11-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
US11203630B2 (en) 2014-03-20 2021-12-21 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
US10442851B2 (en) 2014-03-20 2019-10-15 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
EP3325641A4 (fr) * 2015-07-17 2019-04-24 The University of Chicago Procédés et composition de modification d'enzymes
US11459400B2 (en) * 2015-07-17 2022-10-04 The University Of Chicago Methods and composition for modifying enzymes
US20180208678A1 (en) * 2015-07-17 2018-07-26 The University Of Chicago Methods and composition for modifying enzymes
US11434275B2 (en) 2015-09-23 2022-09-06 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
US10766946B2 (en) 2015-09-23 2020-09-08 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type III domains
US11680091B2 (en) 2018-02-23 2023-06-20 The University Of Chicago Methods and composition involving thermophilic fibronectin type III (FN3) monobodies

Similar Documents

Publication Publication Date Title
WO2008031098A1 (fr) Bibliothèques d'acides aminés binaires pour monocorps polypeptidiques de fibronectines de type iii
CA2583009C (fr) Conjugues de proteine utilisables en therapie, pour le diagnostic et en chromatographie
JP4578768B2 (ja) 人工抗体ポリペプチド
JP4369662B2 (ja) 単量体ドメインのコンビナトリアルライブラリー
US7691970B2 (en) Muteins of a bilin-binding protein with affinity for a given target
US7598352B2 (en) Method of identifying polypeptide monobodies which bind to target proteins and use thereof
WO2005019256A2 (fr) Muteines de lipocaline lacrymale
JP2001500531A (ja) 人工抗体ポリペプチド
JP2010187667A (ja) 単量体ドメインの組み合わせライブラリー
CN105120885B (zh) 从植物半胱氨酸蛋白酶抑制剂衍生的支架蛋白
JP2007513602A (ja) ポリペプチドディスプレイライブラリ並びにそれらの作製及び使用方法
JP2016523088A (ja) ペプチドの細胞輸送をモニタリングする方法
JP5904565B2 (ja) 微小タンパク質の骨格構造に基づく分子ライブラリ
EP1773994B1 (fr) Polypeptide
US20120283136A1 (en) Compositions and methods for the rapid biosynthesis and in vivo screening of biologically relevant peptides
Zwick et al. Homodimeric peptides displayed by the major coat protein of filamentous phage
Yasui et al. A sweet protein monellin as a non-antibody scaffold for synthetic binding proteins
WO2007114139A1 (fr) Expression phagique par un nouveau bactériophage filamenteux
Bowen Engineering Post-Translationally Modified Peptides by Combinatorial Screening
Lutz Novel Backbone Methods for De Novo Protein Design
CN115997051A (zh) 蛋白质支架
Rajagopal Directed evolution of a beta-sheet scaffold for targeting proteins involved in human disease–Thrombin and the vascular endothelial growth factor (VEGF)
Jackrel Design of tetratricopeptide repeat proteins with novel binding specifications
Wilbur Conformational switches regulate clathrin mediated endocytosis
Luisi Identification of novel protein scaffolds for small molecules binding and for catalysis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814777

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07814777

Country of ref document: EP

Kind code of ref document: A1